Drug intelligence / Profile preview

ND-340

Development stage: Phase 1
Lead developer: Nang Kuang Pharmaceutical
Modality: Small Molecules
Administration: Intramuscular (via Nerve Block)

Overview

ND-340 is a small molecule drug developed by Nang Kuang Pharmaceutical Co., Ltd. It is primarily indicated for postoperative pain management. The drug is administered as an extended-release injectable suspension and is currently in Phase 1 clinical trials.

Other names: bupivacaine extended-release injectable suspensionbupivacaine microspheres

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on ND-340.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND-340.